More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid-acting insulin biosimilar for the first time. The agency has ...

Merilog, a biosimilar to Novolog, offers a more affordable insulin option for type 2 diabetes patients, enhancing treatment accessibility. The GEMELLI-1 trial confirmed Merilog's noninferiority to the ...

IQ+, our most advanced algorithm ever, together with the benefits of Abbott's latest CGM sensor on our tested and trusted ...

Sanofi (NASDAQ:SNY) has received FDA approval for Merilog, a biosimilar of Novo Nordisk's (NVO) rapid-acting insulin product NovoLog, for the improvement of glycemic control in adults and children ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog (insulin aspart), for treating adults and children with diabetes. The approval ...

Kirsty 100units/mL is supplied as a 3mL single-patient-use prefilled pen as well as a 10mL multiple-dose vial. The approval of insulin aspart-xjhz was supported by a comprehensive data package that ...

Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly. The Danish drugmaker said Tuesday that pre-filled pens and ...

WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently approved Merilog (insulin-aspart-szjj) as the first rapid-acting insulin biosimilar to Novolog (insulin aspart). This new ...

HOUSTON — The American Diabetes Association (ADA) said it's concerned about the impact of potential shortages of certain types of insulin. Across the country, people are reporting having trouble ...

Certain brands of insulin have been periodically in shortage since late 2023. The shortages caught the attention of patient advocates and members of Congress who have demanded answers from the ...